Novartis buys BASF's generic drugs business

A subsidiary of Switzerland's Novartis is to paying SFr174 million ($102 million) for German group BASF's European generic drug business.

This content was published on December 4, 2000 - 14:50

Novartis Generics announced on Monday that the acquisition includes companies in six European countries and, subject to regulatory approvals, will be effective from January 2001.

Oswald Sellemond, Head of Novartis Generics, said: "This acquisition will give us rapid entry into new markets in addition to enhancing our presence in areas that are attractive for the future. We are taking a significant step towards our goal of being present in every major generics market."

The six BASF Pharma generics companies are based in Germany, France, Italy, the Netherlands, Switzerland, and Spain. Overall, they employ 224 people and generate total annual sales of SFr91 million.

For BASF, the sale is consistent with its strategy - announced at the beginning of the year - of focusing on prescription drugs.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.